AU2014365888B2 - Survivin-directed cancer vaccine therapy - Google Patents

Survivin-directed cancer vaccine therapy Download PDF

Info

Publication number
AU2014365888B2
AU2014365888B2 AU2014365888A AU2014365888A AU2014365888B2 AU 2014365888 B2 AU2014365888 B2 AU 2014365888B2 AU 2014365888 A AU2014365888 A AU 2014365888A AU 2014365888 A AU2014365888 A AU 2014365888A AU 2014365888 B2 AU2014365888 B2 AU 2014365888B2
Authority
AU
Australia
Prior art keywords
survivin
truncated
cancer
dotap
liposomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2014365888A
Other languages
English (en)
Other versions
AU2014365888A1 (en
Inventor
Patrizia BONIFORTE
Simon Geissler
Kenneth HANCE
Stefan Jaekel
Roland Kellner
Dirk MUELLER-POMPALLA
Joerg PLASCHKE
Thomas Rysiok
Markus Weigandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2014365888A1 publication Critical patent/AU2014365888A1/en
Application granted granted Critical
Publication of AU2014365888B2 publication Critical patent/AU2014365888B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2014365888A 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy Expired - Fee Related AU2014365888B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005831.6 2013-12-16
EP13005831 2013-12-16
PCT/EP2014/003384 WO2015090572A1 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Publications (2)

Publication Number Publication Date
AU2014365888A1 AU2014365888A1 (en) 2016-07-28
AU2014365888B2 true AU2014365888B2 (en) 2018-12-06

Family

ID=49884863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014365888A Expired - Fee Related AU2014365888B2 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Country Status (8)

Country Link
US (1) US20160279213A1 (cg-RX-API-DMAC7.html)
EP (1) EP3083663A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017501172A (cg-RX-API-DMAC7.html)
CN (1) CN105873941A (cg-RX-API-DMAC7.html)
AU (1) AU2014365888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2933705A1 (cg-RX-API-DMAC7.html)
IL (1) IL246299A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015090572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
CN109125741B (zh) * 2018-08-13 2022-02-11 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111983240B (zh) * 2020-08-27 2023-11-21 天津大学 一种产气荚膜梭菌α毒素可视化检测的方法
JP7318983B2 (ja) * 2021-12-21 2023-08-01 株式会社アビー 細胞凍結保存液、及び細胞凍結方法
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
AU2009236306B2 (en) * 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sun, C. et al., "Solution Structure of Human Survivin and Its Binding Interface with Smac/Diablo", Biochemistry. 2005, vol. 44, pages 11-17. *

Also Published As

Publication number Publication date
IL246299A0 (en) 2016-07-31
EP3083663A1 (en) 2016-10-26
US20160279213A1 (en) 2016-09-29
WO2015090572A1 (en) 2015-06-25
JP2017501172A (ja) 2017-01-12
CA2933705A1 (en) 2015-06-25
CN105873941A (zh) 2016-08-17
AU2014365888A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US20160279213A1 (en) Survivin-Directed Cancer Vaccine Therapy
Wu et al. CASTING: A potent supramolecular strategy to cytosolically deliver STING agonist for cancer immunotherapy and SARS-CoV-2 vaccination
US10729766B2 (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
AU2008252911B2 (en) Lyophilised antigen composition
EP2292258A1 (en) Multiepitope vaccine for Her2/neu-associated cancers
KR20170063780A (ko) 지질과 리포좀의 안정된 제제
KR102375057B1 (ko) Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물
JP7082110B2 (ja) アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
KR20210052924A (ko) 작은 지질 나노 입자 및 이를 포함하는 암 백신
US20250302975A1 (en) Methods and compositions for agonising tlr3
KR20250115903A (ko) 데옥시콜산과 연결된 암항원 펩타이드를 포함하는 나노구조체 및 이의 용도
HK40004722B (en) Rna formulation for immunotherapy
KR20240158819A (ko) 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도
HK40004722A (en) Rna formulation for immunotherapy
HK1220914B (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee